SecSonar.com

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Charles River Laboratories International, Inc. (CRL) is a Medical - Diagnostics & Research company based in US with a market capitalization of $8.9B. Revenue declined 0.8% year-over-year and the company generated $518.5M in free cash flow. This page tracks CRL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 18.7K employees · IPO Jun 23, 2000

Valuation

Valuation & price

$150.85 · as of May 17, 2026 · -34.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.80

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$231$190$149Jul 25Dec 25Jul 26Jul 7, 25$153.90Jul 9, 25$158.97Jul 11, 25$159.40Jul 15, 25$154.42Jul 17, 25$156.70Jul 21, 25$149.79Jul 23, 25$167.95Jul 25, 25$176.93Jul 29, 25$178.45Jul 31, 25$169.64Aug 4, 25$167.92Aug 6, 25$150.33Aug 11, 25$148.93Aug 13, 25$155.00Aug 15, 25$156.68Aug 19, 25$158.48Aug 21, 25$154.54Aug 25, 25$164.11Aug 27, 25$162.80Aug 29, 25$163.31Sep 3, 25$162.33Sep 5, 25$163.99Sep 9, 25$157.38Sep 11, 25$159.74Sep 16, 25$151.60Sep 18, 25$156.99Sep 22, 25$153.89Sep 24, 25$149.45Sep 26, 25$148.56Sep 30, 25$156.46Oct 2, 25$175.36Oct 6, 25$174.95Oct 8, 25$173.47Oct 10, 25$167.03Oct 14, 25$170.13Oct 16, 25$174.95Oct 21, 25$188.26Oct 23, 25$190.97Oct 27, 25$195.28Oct 29, 25$180.15Oct 31, 25$180.07Nov 4, 25$177.85Nov 6, 25$170.88Nov 10, 25$168.97Nov 12, 25$171.50Nov 14, 25$167.81Nov 18, 25$162.53Nov 20, 25$162.08Nov 25, 25$178.05Nov 28, 25$178.14Dec 2, 25$174.76Dec 4, 25$184.04Dec 8, 25$187.12Dec 10, 25$194.85Dec 12, 25$193.03Dec 16, 25$195.22Dec 18, 25$193.85Dec 22, 25$203.02Dec 24, 25$203.16Dec 29, 25$203.16Jan 2, 26$202.42Jan 6, 26$216.11Jan 8, 26$215.51Jan 12, 26$218.82Jan 14, 26$216.39Jan 16, 26$219.70Jan 21, 26$226.77Jan 23, 26$219.61Jan 27, 26$219.53Jan 29, 26$211.68Feb 2, 26$213.22Feb 4, 26$201.62Feb 9, 26$185.70Feb 11, 26$165.98Feb 13, 26$161.35Feb 18, 26$158.00Feb 20, 26$168.92Feb 24, 26$166.06Feb 26, 26$175.46Mar 2, 26$178.61Mar 4, 26$179.58Mar 6, 26$174.46Mar 10, 26$167.37Mar 12, 26$152.66Mar 17, 26$153.71Mar 19, 26$153.05Mar 23, 26$158.00Mar 25, 26$165.89Mar 27, 26$159.16Mar 31, 26$172.50Apr 2, 26$173.89Apr 7, 26$169.54Apr 9, 26$175.55Apr 13, 26$178.34Apr 15, 26$180.56Apr 17, 26$183.88Apr 22, 26$184.80Apr 24, 26$169.80Apr 28, 26$166.79Apr 30, 26$166.97May 4, 26$172.32May 6, 26$181.73May 8, 26$177.62May 12, 26$168.69May 14, 26$159.12May 18, 26$149.93May 20, 26$156.03May 22, 26$160.30May 28, 26$181.34Jun 1, 26$182.07Jun 3, 26$179.87Jun 5, 26$181.34Jun 9, 26$189.85Jun 11, 26$188.06Jun 15, 26$188.47Jun 17, 26$182.34Jun 22, 26$181.56Jun 24, 26$202.10Jun 26, 26$215.75Jul 2, 26$230.69
$145.5752-week range$230.69
Loading valuation history…

Fundamentals

Key fundamentals

$8.9B

Market cap

-0.8%

Revenue growth (YoY)

30.5%

Gross margin

$518.5M

Free cash flow (USD)

$2.9B

Net debt

-3.5%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.7BFY 2017$1.9BFY 2018$2.3BFY 2019$2.6BFY 2020$2.9BFY 2021$3.5BFY 2022$4.0BFY 2023$4.1BFY 2024$4.0BFY 2025$4.0B
$1.7B$4B

Free cash flow by year

2016 → 2025

FY 2016$243.0MFY 2017$233.8MFY 2018$301.1MFY 2019$340.4MFY 2020$380.0MFY 2021$532.0MFY 2022$294.9MFY 2023$365.4MFY 2024$501.6MFY 2025$518.5M
$243M$518.5M

Gross margin by year

2021 → 2025

FY 202137.7%FY 202236.8%FY 202336.4%FY 202432.9%FY 202530.5%
37.7%30.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $16.9M · 10b5-1 PlanFOSTER JAMES C · Director · $16.9MJul 1, 2026Filing
  • 8-K eventLong-Term Incentive Plan AdoptedMay 11, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing

Questions

Frequently asked questions

What is Charles River Laboratories International, Inc.'s market cap?

Charles River Laboratories International, Inc. (CRL) has a market capitalization of $8.9B.

What is CRL's P/E ratio?

A meaningful P/E ratio is not available for CRL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CRL's price-to-book (P/B) ratio?

CRL trades at 2.80 times book value per share.

Are insiders buying CRL stock?

SEC Form 4 filings show no open-market insider buys at Charles River Laboratories International, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Medical - Diagnostics & Research

QGEN

Qiagen N.V.

$7.6B

ICLR

ICON Public Limited Company

$10.5B

RVTY

Revvity, Inc.

$11.6B

MEDP

Medpace Holdings, Inc.

$12.9B

SHC

Sotera Health Company

$4.5B

RDNT

RadNet, Inc.

$4.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.